Abstract
Annually, millions of humans and animals suffer from chronic and acute pain, creating welfare and quality of life concerns for both humans and animals. There is a need to develop new and effective analgesic options as alternatives to opioids and non-steroidal anti-inflammatories (NSAIDs) for humans and animals. A major challenge in developing novel therapeutic approaches is accurately measuring the impact of pain in animal models in a way that is clinically relevant and predictive of clinical efficacy. The Pain in Animals Workshop (PAW) meetings are held every other year in partnership with the National Institutes of Health (NIH), bringing key stakeholders together to improve our understanding of the impact of pain in humans and animals and determine how best to measure this impact. The 2025 workshop explored the following topics: - Current perspectives on non-rodent models, - Artificial intelligence applied to the measurement of pain, - Evolutionary clues to pain mechanisms and novel measures, - Breed and sex differences in pain sensitivity (perceptions and reality). The workshop brought together academic, government, and industry experts. Under the topic of ‘Current perspectives on non-rodent models’, current views regarding such models were discussed, whilst also showcasing and discussing recent NIH funded/ongoing programs involving these models. With the current interest in non-rodent models and spontaneous disease models, the discussion on successes and challenges was timely. Given the topic's importance and the meeting's uniqueness, this narrative summarizes the presentations and discussions on the topic of current perspectives on spontaneous and other non-rodent disease models.
Introduction
There is a very high burden of chronic or persistent pain in humans, and thus a significant impact on individuals and society (). Current treatments are limited and there is an ongoing need to develop new and effective analgesic options as alternatives to the current treatment options: opioids, that contribute to the opioid epidemic, and non-steroidal anti-inflammatories (NSAIDs), which can be associated with significant side effects. Despite exponentially increasing biomedical pain research (), studies using current translational models are not resulting in enough effective novel therapeutics for chronic pain (, ). Indeed, it was recently stated that “despite generating a plethora of novel analgesic targets, pharmaceuticals for chronic pain treatment remain largely limited to the same 6 drug classes as present 40 years ago” (). The failure of translational chronic pain research has been discussed with emphasis on the models and outcome measures in pre-clinical research (, –). The majority of preclinical models are induced (i.e., created) to model or mimic the target clinical conditions. While these models have increased our mechanistic understanding of pain conditions, they have not worked as well for selecting new analgesic drug candidates (, ). This has led to suggestions to utilize non-rodent models, including spontaneous disease models in non-rodent animals, to help inform pain therapeutic development. At the Pain in Animals Workshop (PAW) meeting in 2025, this topic (‘Current Perspectives: Non-Rodent Models’) was discussed. The 2-day Pain in Animals Workshop was held on September 26 and 27, 2025, at the National Institutes of Health campus, Bethesda, Maryland. The full agenda can be found in Supplementary File 1. This narrative is one product from that meeting, summarizing the presentations and discussions on the topic of ‘Current perspectives on non-rodent models’ from the workshop. This narrative is complementary to the recordings of these presentations and discussion at the workshop, which are archived at the NIH and are available at: Day 1, https://videocast.nih.gov/watch/d857b03d-d5db-11f0-9cf9-12c45c580ad9
Michele Sharkey PAW plenary lecture: cross-species insights into dorsal root ganglion biology: unraveling the mechanisms of pain
Dr. Ted Price gave the Michele Sharkey PAW Plenary lecture, describing and discussing his work with human tissues from patients suffering pain, and how such an approach could be extended to other species.
For decades pain researchers have mostly relied on rodent pain models to try to understand pain mechanisms and identify therapeutic targets for the treatment of pain in human patients. While this has led to important fundamental advances in our understanding of pain mechanisms, it has mostly not led to the identification of new targets that have been developed into new treatments for pain in the clinic. While there are many potential reasons for this, one glaring hole in our understanding of pain is our knowledge of the fundamental molecular features of the human pain pathway (, ). With advances in single cell and spatial transcriptomics, as well as progress in other areas like proteomics and increased access to precious human tissues, our understanding of the pain pathway is rapidly changing in many species, including in humans (–).
Dr. Price described what we now know about human pain sensing neurons in the peripheral nervous system, called nociceptors. The focus was on what we understand about how these cells change in people with neuropathic and other forms of chronic pain based on studies on human dorsal root ganglion tissues from rare surgeries where the dorsal root ganglia (DRG) is removed as part of the normal course of the surgery, or from DRG recovered from organ donors. Using single cell and spatial transcriptomics, as well as patch clamp electrophysiology, an emerging theme coming from these studies is that spontaneous action potential generation is frequently seen in neurons associated with neuropathic pain (, ). This effect may be driven by changes in voltage-gated sodium channels like Nav1.8 because selective inhibition with suzetrigine, blocks spontaneous activity (), and because Nav1.8 mRNA expression is increased in these sensitized neurons as measured in patch-seq experiments (). Another emerging area is the notion that neurodegeneration within the human dorsal root ganglia may play a key role in diabetic neuropathic pain. Recent observations of neuronal loss accompanied by the formation of Nageotte Nodules, small, neuroma-like structures first described by Jean Nageotte in the 1920's, are consistent with a link between neuronal degeneration and surviving neuron pathology that could drive pain in diabetic neuropathy (). Interestingly, these Nageotte Nodules have been observed in the dorsal root ganglia in other species associated with viral sensory neuropathy (, ), and this was an area of discussion during the poster session at the PAW meeting.
As opposed to neuropathic pain where numerous neuronal transcriptomic changes are seen, it appears that non-neuronal cells show the biggest changes in dorsal root ganglia recovered from people with a history of chronic pain that does not have neuropathic qualities, suggesting that ongoing pain drivers within the ganglia originating in non-neuronal cell types might play an important role in non-neuropathic, persistent (chronic) pain (). Such differences between different naturally occurring pain types are crucial to understand. Pain associated with arthritis is the most common cause of chronic pain affecting humans and other large mammals, including cats and dogs, and so future work should focus on understanding how dorsal root ganglia neurons change in mammals with naturally occurring painful arthritic diseases. This creates an enormous opportunity for collaboration between neuroscientists and veterinary medicine because the opportunity to procure tissues, such as dorsal root ganglia tissues, from subjects with arthritis pain is likely far greater in companion and production animals. Leveraging such an opportunity is likely to advance discovery of better targets for arthritic pain. With this opportunity in mind, Dr. Price discussed how our understanding of naturally occurring pain mechanisms in humans is, and is not, reflected in rodent models of pain and why there should be more research on understanding pain mechanisms using tissues obtained from veterinary chronic pain cases. These kinds of studies represent an excellent opportunity to understand how pain mechanisms are conserved across species, allowing researchers to focus on targets that can be assessed for clinical efficacy in veterinary medicine prior to, or in parallel with human pain trials.
The current role of non-rodent animal models in pain research
Dr. Julia Bachman provided an overview of the current perspective on non-rodent models, highlighting their advantages, but also the challenges, while emphasizing that the most appropriate model(s) will vary with the context of use, such as the stage of research and therapeutic development, and the pain state being investigated.
Understanding and treating pain requires research tools and approaches that reflect the complexity of biological systems, clinical syndromes, and patient variability. While rodent models remain essential for early discovery and mechanistic insights, non-rodent animal models, including those with naturally occurring pain, play a critical and increasingly recognized role in translational pain research. Dr Bachman provided an overview of the current state of non-rodent animal models in pain science, with a particular emphasis on companion animals experiencing spontaneous conditions as these models offer scientifically relevant platforms for evaluating analgesics –benefiting both veterinary and human medicine.
Non-rodent models add unique value, including improved alignment with human anatomy, physiology, and clinically relevant endpoints, as well as access to and the ability to employ advanced imaging, functional assessment tools, and non-pharmacological therapeutic approaches. However, there are challenges when using non-rodent models. These include the wide variability in pain expression both within and across different species – for example, the inherent differences between canine and ovine behavior related to one being a predator species (that has the luxury to be more demonstrative in response to pain), and the other a prey species (behavioral responses to pain are muted, or ‘hidden’). With multiple species being considered, this multiplies the required work to develop validated outcome measures in each species. Just as it applies to rodent models, context-appropriate model selection is important, which requires a deep understanding of species-specific behavior, and even understanding behavioral differences within a species. Dr Bachman prompted researchers to consider what it means for a model or measure to be validated, noting the varied terminology and types of validity, and highlighted issues that arise when trying to validate models and outcome measures in parallel.
Recommendations from recent strategic planning efforts conducted as part of the NIH's Helping End Addiction Long-term® Initiative (the NIH HEAL Initiative®) include the development of a new generation of highly predictive disease-specific animal and cellular models (), while ongoing efforts focused on discovery research in human pain biology create enormous opportunity for “back translation” of these findings to models used for both basic and translational research. Emerging methodologies—such as organ-on-chip systems, human-derived nociceptors, and in silico models are also important ‘non-rodent’ model systems that can complement and cross-inform traditional approaches, as they can enhance study design and reduce reliance on rodent and other research animal models where appropriate.
Recognizing that no single model fits all purposes, there is a need for multidisciplinary expertise in choosing and implementing the appropriate animal model(s) for pain research. Input from veterinarians, clinicians and pain researchers, behaviorists, statisticians, and regulatory scientists is essential to ensure rigor and scientific relevance. By leveraging diverse models, scientific expertise, and collaborative frameworks, the field can make meaningful progress toward understanding and alleviating pain in all species.
A comparative approach to the leaky gut and osteoarthritis
Dr. Amanda Nelson is the project leader for an NIH funded study involving humans and pet dogs: Is the gut important in multiple joint osteoarthritis? A multimodal investigation in humans and pet dogs (https://www.med.unc.edu/medicine/rheumatology-allergy-immunology/people/amanda-e-nelson-md-mscr/). She provided an overview of the project, the rationale for concurrently using pet dogs and humans, and discussed early results demonstrating the fidelity between multijoint OA (MJOA) in the two species.
Osteoarthritis is the most common form of arthritis in both humans and pet dogs and frequently involves multiple joint sites. Multiple joint osteoarthritis suffers from a lack of standard classification criteria in both humans and pet dogs, but is widely recognized clinically and is suggestive of a more systemic process (). Intestinal permeability and microbial dysbiosis contribute to low-grade systemic inflammation in a variety of conditions commonly comorbid with OA (e.g., diabetes, obesity) (), leading us to explore a potential role for these factors in MJOA. The shared frequency and contributing factors in both humans and pet dogs suggest that pet dogs provide a relatively untapped model of disease with shorter time to progression () and potential to develop therapeutics for both humans and dogs.
The study was designed as a parallel prospective community-based cohort study in humans and in pet dogs (NIAMS R01AR080733) to investigate the frequency and risk factors for MJOA, with a focus on intestinal permeability and the microbiome as contributors to low grade systemic inflammation (initial results have been published ).
Human participants were recruited from the community-based Johnston County Health Study (JoCoHS, PI: Nelson ), along with an independent cohort of pet dogs recruited to NC State College of Veterinary Medicine (PI: Lascelles). Questionnaires, functional assessments, standardized multiple joint radiographs and pain assessments, blood and fecal samples were obtained in all participants (human and dog). In the canine population, validated owner (proxy) questionnaires and veterinarian pain assessments, as well as objective measures of activity, sensitivity and limb use were employed to match the human assessments, as recently communicated (). Microbiome analysis was done by 16S rRNA amplicon sequencing. MJOA was defined as ≥3 unique joint sites (bilateral joint=1 site) involved; symptom burden was based on validated self-reported/proxy measures of pain. Intestinal permeability was directly assessed using sugar-based assays: a lactulose:mannitol dual sugar test in humans, and an iohexol-based absorption test in dogs. Descriptive statistics and Spearman correlations with Benjamini-Hochberg correction for multiple testing were used to determine relationships among lab tests, pain, intestinal permeability, and microbiome diversity measures.
Human participants (n = 100, 63% women, mean age 56 years, mean body mass index 34 kg/m2) and pet dogs (n = 115, 40% spayed females, 57% neutered males, mean age 8 years, mean weight 27 kg) were included in preliminary analyses. A nearly identical proportion, 20% in each cohort, had radiographic MJOA. The most common sites in humans were knees, hands and feet, while in dogs the hips were most frequently affected followed by shoulder and elbow. Several members of each cohort had OA in more than 4 sites, reflecting a high OA burden. Clinical lab assessments (e.g., blood counts, liver function, glucose) were generally unremarkable, and similar in the human and dog cohorts. The frequency of directly assessed intestinal permeability was low in both cohorts regardless of MJOA status.
Microbial α-diversity did not differ statistically between participants with or without MJOA, although a few taxa were differentially abundant by MJOA status. Additionally, lower levels of genera Christensenellaceae and Lachnoclostridium in humans, and butyrate-producing Faecalibacterium in dogs, were correlated with greater pain severity, as were higher levels of Escherichia-Shigella in dogs and were statistically significant.
In this unique, parallel, community-based study of naturally occurring MJOA in humans and pet dogs, early results identified similar patterns of radiographic and symptomatic multiple joint involvement in both cohorts, supporting the use of dogs to model naturally occurring MJOA. Taxa potentially related to radiographic MJOA and pain were identified in this preliminary analysis, providing new insights into links between dysbiosis and MJOA. The logistically cumbersome ‘gold standard’ tests for intestinal permeability did not demonstrate strong associations with MJOA (), and controversy regarding the best method for assessment persists. Future planned work in this project will incorporate additional assessments (e.g., circulating biomarkers, cytokines, indirect measures of intestinal permeability) as well as longitudinal assessments in both the human and canine cohort to further understand these relationships.
Overall, our work so far suggests high fidelity between human and dog MJOA burden, and other health characteristics, supporting further work in the dog model of naturally occurring MJOA, including testing interventions. Such ‘trials’ would result in more rapid readouts than similar trials in humans.
Cross-species validation of B cell-mediated neuropathic pain: From rodents to pigs and beyond
Dr. Peter Grace leads an NIH funded study involving murine and piglet models: Regulation of peripheral neuropathic pain by B-cells (https://reporter.nih.gov/search/Pubv45yjkkK6VSMkjG8sBw/project-details/10798311). He provided an overview of the project, describing the results found in the mouse model, and then described the validation work in a piglet model – a model that reflects real-world husbandry approaches in piglets. The rationale for incorporating the piglet model was also discussed.
Pain arising from a lesion or disease of the somatosensory system—neuropathic pain—remains refractory to current analgesics (). Neuroimmune interactions have emerged as central to initiation and persistence of this pain (, ) Recent work from our group has shown that peripheral nerve injury leads to activation and differentiation of B cells, potentially due to the de novo expression of autoantigens (–). Secreted IgG forms immune complexes with de novo antigenic epitopes expressed after nerve injury to activate Fcγ receptor (FcγR)-expressing cells in dorsal root ganglia (DRG) and the spinal cord, which leads to neuronal hyperexcitability and mechanical allodynia (–). However, this mechanistic work was performed in mice, with human DRG sections confirming IgG accumulation (–).
Recent, unpublished work is revealing that peripheral nerve injury induces clustering of B cells, follicular helper T cells, dendritic cells, and stromal cells into clusters in the DRG meninges that resemble tertiary lymphoid structures, including high endothelial venules and lymphatic elements. These structures have potential to promote ongoing germinal center–like activity and class-switched IgG production in close proximity to sensory neuron somata, amplifying neuroimmune crosstalk that maintains neuropathic pain.
To determine whether these processes may be conserved in higher species, we investigated routine tail docking in a non-rodent model - piglets - as a model of traumatic nerve injury and potential chronic neuropathic pain. Tail docking was performed within the first week of life and resulted in neuroma formation at the stump for at least 12 weeks, with prior work demonstrating long-lasting mechanical sensitization, altered gait, and changes in posture and feeding behavior consistent with ongoing pain (–). Porcine and human immune systems share substantially greater similarity than mouse and human, enhancing the translational relevance of immune mechanisms identified in this model ().
In tail-docked piglets, DRG harvested 42 days post-procedure showed marked IgG immunoreactivity compared with sham-operated littermates, indicating deposition of IgG within caudal ganglia that parallels findings in mouse lumbar DRG after nerve injury. B cells and macrophages cluster within the connective tissue surrounding piglet DRG cell bodies, echoing the tertiary lymphoid–like architecture observed in mouse DRG meninges and suggesting that local germinal center–like activity and FcγR-bearing myeloid effectors are also engaged in the porcine system. A comprehensive longitudinal protocol is underway that aligns behavior and biochemical assessments with these observations.
Collectively, these cross-species data support the B cell–IgG response as a conserved immune response to traumatic nerve injury, and likely relevant to human pain conditions. Establishing pain-related behavioral correlates in the piglet model will enable rigorous evaluation of B cell–targeted and FcγR-modifying therapeutics in a large animal with immune features closer to humans, addressing current gaps in the translation of neuroimmune pain mechanisms. This work ultimately aims to validate B cell–directed strategies as a novel class of analgesics for neuropathic pain patients who currently lack effective, mechanism-based treatments.
Canine biopsychosocial model of osteoarthritis
Dr. Margaret Gruen is the project leader for an NIH funded study involving pet dogs: Innovative modeling of the biopsychosocial model in animals: Validation of outcomes for assessing emotional and cognitive domains affected by naturally occurring chronic pain in dogs (https://reporter.nih.gov/search/ZSw6VjMHP0GnqF9GaBjvtQ/project-details/11050788). She discussed the need for comprehensive measures of emotion and cognition in animal models and provided the rationale for developing these measures in the spontaneous pet dog model of OA pain.
Chronic pain conditions remain a major public health burden, with OA the leading cause of persistent pain and disability. In the United States, painful OA affects nearly 90 million adults, profoundly impairing quality of life and contributing to anxiety, depression, pain catastrophizing, and cognitive dysfunction (–52). These psychological dimensions are central to the chronic pain experience, yet they are poorly represented in most existing preclinical models. Dogs with naturally occurring OA pain offer an opportunity to address this gap. Canine OA closely parallels human disease in pathology, chronicity, and functional impact, including gait abnormalities, sleep disturbances, reduced activity, and owner-reported impairments (53–55). Importantly, dogs display relevant emotional (56) and cognitive processes (57, 58) and live in shared environments with humans, making them uniquely suited to model the biopsychosocial complexity of chronic pain.
To address the need for comprehensive measures of emotion and cognition that are relevant to pain in dogs, our group has developed a set of assessments (the Dog Pain-Related Emotion and Cognition Test Battery, DECTB-P) that will allow evaluation of these domains. The first phase of this study focused on construction and refinement of the DECTB-P, integrating validated assays of affect (anxiety, depression-like behavior, catastrophizing) (59) and cognition (working memory, attention, inhibitory control, judgment bias) (57) with owner-reported assessments (Client-reported outcome measures). Novel measures, such as spatial discounting and anhedonia assessments, have been developed to expand evaluation of pain-related domains. Spatial discounting is a task used to measure emotional decision making, where the distance to a larger food reward is increased sequentially, and the distance at which a dog ’switches’ to retrieve a closer, smaller treat is recorded. Anhedonia, or loss of enjoyment in pleasurable activities, is assessed through evaluation of a dog's willingness to engage with their owner and with a food-delivery device. Spontaneous measures of dogs’ responses to enjoyable activities in the home are also being collected. Tasks have been optimized for feasibility, efficiency, and minimal redundancy (Table 1).
Table 1
| Category | Domain affected in humans | Test in dogs | |
|---|---|---|---|
| Emotion/Affect | Anxiety | Surprising event/Attention bias (PM) | |
| CBARQ, Lincoln Sound Sensitivity Scale (CROMs) | |||
| Depression | Anhedonia (PM) Exercise and greeting response (PM) Canine owner reported quality of life scale (CORQ) | ||
| Pain catastrophizing | Conditioned heat paradigm (PM) | ||
| Cognitive function | Executive function | Attention/attentional interference | Spatial working memory with distraction (PM) |
| Working memory | Sustained attention (PM) | ||
| Holeboard test of spatial working memory and reversal (PM) | |||
| Inhibitory control | Cylinder & detour (PM) | ||
| Emotional decision making | Judgement bias (PM) | ||
| Spatial discounting (PM) | |||
| General cognition | Unsolvable task (PM) | ||
| CAnine DEmentia Scale (CADES) (CROM) | |||
Tasks included in the Dog Pain-Related Emotion and Cognition Test Battery (DECTB-P).
Canine battery elements are based on the domains assessed and relevance to affected domains in humans with chronic pain. PM, performance measure; CROM, client reported outcome measure; CBARQ, Canine Behavioral and Research Questionnaire.
Using the DECTB-P, the next phase of the study will evaluate the battery's validity and responsiveness. In a cohort of dogs with and without OA pain, we will assess discriminative validity, test–retest reliability, and structural validity, benchmarking against gold-standard pain measures including the Canine Brief Pain Inventory, gait asymmetry, and accelerometry (53, 60, 61). Responsiveness of the battery will be tested through a blinded, randomized, placebo-controlled longitudinal analgesic trial in dogs with OA. Advanced statistical modeling, including factor analysis and item response theory, will refine the DECTB-P into a concise, clinically practical tool. Finally, videos and protocols will be developed that will allow other pain researchers to incorporate these measures into their studies, improving the translational relevance of the spontaneous OA pain model in dogs. These videos and protocols will also allow assessment of these domains in clinical canine patients and expand the cross-species comparative applications of this work.
Through development of the DECTB-P, this work will produce the first validated, naturally occurring animal model of chronic pain incorporating measurable biological and psychological outcomes. Ultimately, the canine OA model with integrated emotional and cognitive measures will accelerate development of effective non-opioid therapies and advance mechanistic understanding of chronic pain. The current work and the DECTB-P covers psychological domains; in the current work, social factors that may influence pain are not directly measured. Candidate social factors include the caregiver, caregiver-dog relationship, other pets, and housing and environment. Owner-reported measures of function and cognition/affect likely capture some of this indirectly. Future work should address the ’social’ factors to move the model towards a full ‘biopsychosocial’ model of the pain experience.
Discussion
Presentations focused on the use of non-rodent models in chronic pain translational research. Several interrelated themes (Box 1) emerged from the discussion following the presentations: the (mis)use of the term ‘validation’ in pain research, the challenges of cross-species translation, the role of different animal models, and the importance of integrating biological, behavioral, and environmental complexity when studying pain.
BOX 1
Summary of the main discussion points.
|
A central concern was the field's reliance on the term ‘validated’. Participants argued that the concept is often misused as a binary label, with reference to something being either validated or not, when in reality it reflects a continuum of evidence. All measures, models, and tools exist along a spectrum of support, contingent on context, population, and application. Treating validation as a definitive endpoint risks stagnation. It was cautioned that once a tool is labeled ‘validated’, it may be used inappropriately, and without appropriate critique, outside the conditions under which it was originally assessed. This is of particular concern in translational pain science, where instruments may not generalize across species, conditions, or different formats of use. Rather than abandoning the term entirely, there was discussion that more specific and precise language should be used when referring to an instrument as validated - specifying what has been validated, in what context, and under what circumstances - and for recognizing validation as an ongoing, iterative process.
The translational research process of moving from rodent models to larger animals and then to humans was also discussed, with participants noting increasing uncertainty in tools (e.g., antibodies), gene annotations, and other biological aspects at each step. Advances in genomics and proteomics were viewed as powerful solutions, enabling the application of unbiased, system-level comparisons across species. While technical limitations, such as incomplete genome annotation in non-rodent, non-human species, still exist, these were framed as solvable problems rather than fundamental barriers. Importantly, some translational difficulties stem not from species differences per se, but from the lack of effective therapeutics (known positives) to serve as appropriate benchmarks. Without access to a known effective therapeutic, it becomes difficult to assess whether a model or measure is truly predictive. In this context, it was noted that highly efficacious treatments, could be viewed as valuable tools in the process of validation of models and outcome measures.
A substantial portion of the discussion focused on the comparative value of different animal models. There was broad agreement that no single species offers a perfect representation of human pain, and that overemphasizing similarities or differences between any one species and humans can be misleading. The common assumption that larger mammals such as pigs or dogs are inherently more human-like than rodents was challenged; all species exhibit meaningful biological differences, and in some domains, it was argued, mice may be as close, or closer, to humans as other mammals. The unique strengths of each species were nonetheless acknowledged. Rodents provide unparalleled genetic tools and mechanistic insights that have been foundational for understanding nociception and neural circuitry, while larger animals, including companion dogs, offer advantages in modeling naturally occurring disease, shared environments, similar comorbidities, comparable psychosocial overlays and complex behaviors.
This led to a consensus view: pain research benefits from a pluralistic approach that leverages multiple species, each selected based on the specific question being asked. Pain is not a unitary phenomenon; conditions such as osteoarthritis, fibromyalgia, and headache differ substantially in their underlying mechanisms and clinical experience - and different models may therefore be appropriate for different pain states. Rather than seeking a single best model, the field should focus on aligning models with the biological and clinical features of interest.
The discussion also highlighted the distinction between induced experimental models and naturally occurring disease. There was strong support for studying animals with spontaneous conditions — such as osteoarthritis in dogs or lameness in livestock — as these may better capture the complexity and chronicity of human pain. Companion animals, in particular, were seen as valuable because they share environments, diets, and even microbiomes with their owners. This shared context may enhance translational relevance, especially for systemic or multifactorial conditions, though participants cautioned against oversimplifying these comparisons and emphasized the need for careful characterization of both similarities and differences.
Another key theme was the multidimensional nature of pain, particularly the integration of sensory, emotional, and cognitive components. While significant progress has been made in understanding peripheral and spinal mechanisms — largely through rodent research — major gaps remain in our understanding of higher-order central processing. Brain imaging tools in humans provide some insight but lack the cellular resolution needed to uncover underlying mechanisms, underscoring the continued importance of animal models with advanced experimental capabilities.
There was also discussion of emerging efforts to study cognitive and affective dimensions of pain in animals, including constructs analogous to catastrophizing. Although still in early stages, there is growing interest in developing behavioral paradigms to capture these aspects in species such as dogs. These approaches may ultimately complement traditional outcome measures such as mobility assessments, providing a more comprehensive picture of pain and its modulation. Challenges in translating such constructs were acknowledged, particularly given differences in communication and cognition across species. Strategies drawn from pediatric or caregiver-based frameworks were suggested as potential analogies.
Finally, the group addressed questions about the fundamental nature of pain across species, including whether brain size or neuron number correlates with pain experience. The consensus was that such comparisons are overly simplistic. The organization and connectivity of neural systems (particularly how nociceptive signals engage distributed brain networks) are likely more relevant than gross anatomical metrics. Across mammals, these systems appear to function as alarm or warning networks, suggesting some shared features of acute pain experience. Chronic pain, however, is likely more variable, shaped by species-specific biology, behavior, and ecological context.
In summary, the discussion underscored the complexity of pain research and the need for nuanced, context-dependent approaches to animal modeling. Key points included the importance of moving beyond binary notions of validation; embracing multiple species and models tailored to specific questions; leveraging advances in molecular and systems biology for cross-species comparison; and expanding outcome measurement to include cognitive and affective dimensions. Together, these perspectives point toward a more integrated and flexible framework for advancing translational pain science.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Author contributions
TP: Writing – original draft, Writing – review & editing. JB: Writing – original draft, Writing – review & editing. AN: Writing – original draft, Writing – review & editing. PG: Writing – original draft, Writing – review & editing. MG: Writing – original draft, Writing – review & editing. DB: Writing – original draft, Writing – review & editing. JC: Writing – original draft, Writing – review & editing. MG: Writing – original draft, Writing – review & editing. CJ: Writing – original draft, Writing – review & editing. MO: Writing – original draft, Writing – review & editing. SR: Writing – original draft, Writing – review & editing. ES: Writing – original draft, Writing – review & editing. BL: Conceptualization, Data curation, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. The PAW 2025 meeting was supported by The Mayday Fund through a grant (PAM-P25-001850) to NC State University College of Veterinary Medicine (PI: BL). Additional support was provided by the NC State College of Veterinary Medicine Comparative Pain Research and Education Center.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author BL declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpain.2026.1999875/full#supplementary-material
References
1.
Institute of America Committee on Advancing Pain Research CaE. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. (2011). The National Academies Collection: Reports funded by National Institutes of Health.
2.
Percie du SertNRiceAS. Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain. Br J Pharmacol. (2014) 171(12):2951–63. 10.1111/bph.12645
3.
HayMThomasDWCraigheadJLEconomidesCRosenthalJ. Clinical development success rates for investigational drugs. Nat Biotechnol. (2014) 32(1):40–51. 10.1038/nbt.2786
4.
Contopoulos-IoannidisDGNtzaniEIoannidisJP. Translation of highly promising basic science research into clinical applications. Am J Med. (2003) 114(6):477–84. 10.1016/S0002-9343(03)00013-5
5.
EisenachJCRiceASC. Improving preclinical development of novel interventions to treat pain: insanity is doing the same thing over and over and expecting different results. Anesth Analg. (2022) 135(6):1128–36. 10.1213/ANE.0000000000006249
6.
SadlerKEMogilJSStuckyCL. Innovations and advances in modelling and measuring pain in animals. Nat Rev Neurosci. (2022) 23(2):70–85. 10.1038/s41583-021-00536-7
7.
HummelMWhitesideGT. Measuring and realizing the translational significance of preclinical in vivo studies of painful osteoarthritis. Osteoarthritis Cartilage. (2017) 25(3):376–84. 10.1016/j.joca.2016.08.007
8.
MogilJS. The translatability of pain across species. Philos Trans R Soc Lond B Biol Sci. (2019) 374(1785):20190286. 10.1098/rstb.2019.0286
9.
MalfaitAMLittleCBMcDougallJJ. A commentary on modelling osteoarthritis pain in small animals. Osteoarthritis Cartilage. (2013) 21(9):1316–26. 10.1016/j.joca.2013.06.003
10.
ClarkJD. Preclinical pain research: can we do better?Anesthesiology. (2016) 125(5):846–9. 10.1097/ALN.0000000000001340
11.
MogilJS. Animal models of pain: progress and challenges. Review. Nat Rev Neurosci. (2009) 10(4):283–94. 10.1038/nrn2606
12.
CopitsBACuratoloMDoughertyPMGereauRWLuoWMartoneMet al. Human pain neuroscience and the next generation of pain therapeutics. Neuron. (2025) 113(9):1304–6. 10.1016/j.neuron.2025.04.005
13.
RenthalWChamessianACuratoloMDavidsonSBurtonMDib-HajjSet al. Human cells and networks of pain: transforming pain target identification and therapeutic development. Neuron. (2021) 109(9):1426–9. 10.1016/j.neuron.2021.04.005
14.
BhuiyanSANagiSSSankaranarayananISemizoglouEUsoskinDYangLet al. A Reference Atlas of the Human Dorsal Root Ganglion. bioRxiv. (2025) 10.1101/2025.11.05.686654
15.
KörnerJHowardDSolinskiHJMancilla MorenoMHaagNFiebigAet al. Molecular architecture of human dermal sleeping nociceptors. Cell. (2026)189(6):1820–35.e22. 10.1101/2024.12.20.629638
16.
BhuiyanSAXuMYangLSemizoglouEBhatiaPPantaleoKIet al. Harmonized cross-species cell atlases of trigeminal and dorsal root ganglia. Sci Adv. (2024) 10(25):eadj9173. 10.1126/sciadv.adj9173
17.
YangLXuMBhuiyanSALiJZhaoJCohrsRJet al. Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine. Neuron. (2022) 110(11):1806–21. 10.1016/j.neuron.2022.03.003
18.
GabrielKADavisOCPalominoSMIshishitaSPoldsamHBrandonJMet al. A molecular map of the human spinal dorsal and ventral horn defines arrangement of neuronal types and glial sex differences. bioRxiv. (2025). 10.1101/2025.10.31.685953
19.
SharmaNFlahertyKLezgiyevaKWagnerDEKleinAMGintyDD. The emergence of transcriptional identity in somatosensory neurons. Nature. (2020) 577(7790):392–8. 10.1038/s41586-019-1900-1
20.
BarryAMSondermannJRLesnakJBXianFFranco-EnzástigaÚO'BrienJAet al. Multi-omic integration with human dorsal root ganglia proteomics highlights TNFα signalling as a relevant sexually dimorphic pathway. Pain. (2025) 166(10):2386–402. 10.1097/j.pain.0000000000003656
21.
UhelskiMLSchaubMKEspinosaFHelesMCortesNLiYet al. Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons with differential pain etiology. Pain. (2026) 167(6):1430–9. 10.1097/j.pain.0000000000003931
22.
NorthRYLiYRayPRhinesLDTatsuiCERaoGet al. Electrophysiological and transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. Brain. (2019) 142(5):1215–26. 10.1093/brain/awz063
23.
YiJYangLWidmanAJToliverABertelsZDel RosarioJSet al. Human sensory neurons exhibit cell-type-specific, pain-associated differences in intrinsic excitability and expression of SCN9A and SCN10A. bioRxiv. (2025) 10.1101/2025.03.25.645367
24.
ShiersSIMazharKWangzhouAHaberbergerRLesnakJBEzejiNAet al. Nageotte nodules in human dorsal root ganglia reveal neurodegeneration in diabetic peripheral neuropathy. Nat Commun. (2025) 16(1):4168. 10.1038/s41467-025-59538-z
25.
LakritzJRBodairAShahNO'DonnellRPolydefkisMJMillerADet al. Monocyte traffic, dorsal root ganglion histopathology, and loss of intraepidermal nerve fiber density in SIV peripheral neuropathy. Am J Pathol. (2015) 185(7):1912–23. 10.1016/j.ajpath.2015.03.007
26.
BurdoTHOrzechowskiKKnightHLMillerADWilliamsK. Dorsal root ganglia damage in SIV-infected rhesus macaques: an animal model of HIV-induced sensory neuropathy. Am J Pathol. (2012) 180(4):1362–9. 10.1016/j.ajpath.2011.12.016
27.
Arendt-TranholmASankaranarayananIPayneCMancilla MorenoMMazharKYapNet al. Transcriptome of the human C2 dorsal root ganglia in C1-2 arthrodesis surgery: insight for neck pain. Brain. (2026) 149(4):1349–64. 10.1093/brain/awaf370
28.
GereauRWSutherlandSPBakerTCampbellCMCruz-AlmeidaYDeBarLLet al. Research recommendations for the HEAL initiative: a path forward for pain research. J Pain. (2026):106301. 10.1016/j.jpain.2026.106301
29.
NelsonAE. Multiple joint osteoarthritis (MJOA): what’s in a name?Osteoarthritis and Cartilage. (2024) 32(3):234–40. 10.1016/j.joca.2023.10.008
30.
MacuraBKieckaASzczepanikM. Intestinal permeability disturbances: causes, diseases and therapy. Clin Exp Med. (2024) 24(1):232. 10.1007/s10238-024-01496-9
31.
MeesonRLTodhunterRJBlunnGNukiGPitsillidesAA. Spontaneous dog osteoarthritis - a one medicine vision. Nat Rev Rheumatol. (2019) 15(5):273–87. 10.1038/s41584-019-0202-1
32.
NelsonAEArbeevaLJohnsonKSavage-GuinSWalkerTEnomotoMet al. Cross-sectional associations of radiographic multiple joint osteoarthritis and symptoms, laboratory values and the gut microbiota: a multimodal study in humans and pet dogs. Osteoarthr Cartil Open. (2025) 7(4):100682. 10.1016/j.ocarto.2025.100682
33.
GolightlyYMRennerJBHelmickCGJordanJMNelsonAE. Looking back on 30+ years of the johnston county osteoarthritis project while looking forward with the johnston county health study: a narrative review. Osteoarthritis Cartilage. (2024) 32(4):430–8. 10.1016/j.joca.2024.01.002
34.
ArbeevaLKrausVBLoeserRGolightlyYMEnomotoHEnomotoMet al. Direct assessment of intestinal permeability as a risk factor for multiple joint osteoarthritis in community cohorts of humans and pet dogs. Presented at: American College of Rheumatology Convergence 2025; Chicago, Illinois. (2025).
35.
SolimanNMoissetXFerraroMCDe AndradeDCBaronRBeltonJet al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurology. (2025) 24(5):413–28. 10.1016/S1474-4422(25)00068-7
36.
GracePMWatkinsLR. Reordering neuroimmune signaling to prevent and resolve chronic pain. Pain. (2025) 166(11S):S19–22. 10.1097/j.pain.0000000000003679
37.
GracePMTawfikVLSvenssonCIBurtonMDLoggiaMLHutchinsonMR. The neuroimmunology of chronic pain: from rodents to humans. J Neurosci. (2021) 41(5):855–65. 10.1523/JNEUROSCI.1650-20.2020
38.
PandeyVKAcharyaTKWillcoxKFDemblaSRamanujanAGriecoARet al. Peripheral nerve injury reduces macrophage efferocytosis to facilitate neuropathic pain. Proc Natl Acad Sci U S A. (2026) 123(1):e2511401122. 10.1073/pnas.2511401122
39.
LacagninaMJWillcoxKFFioreNTGriecoARLiJHeijnenCJet al. Fc gamma receptor IIa signaling from spinal cord astrocytes promotes neuropathic pain in rats. J Pain. (2025) 36:105553. 10.1016/j.jpain.2025.105553
40.
FioreNTWillcoxKFGriecoARDayaniDZuberiYAHeijnenCJet al. Autoreactive immunoglobulin G levels and fc receptor gamma subunit upregulation drive mechanical allodynia after nerve constriction or crush injury. Pain. (2025) 166(12):2804–17. 10.1097/j.pain.0000000000003734
41.
FioreNTWillcoxKFDayaniDZuberiYAHeijnenCJGracePM. Reducing IgG accumulation via neonatal fc receptor (FcRn) blockade relieves neuropathic pain. Brain Behav Immun. (2025) 125:371–87. 10.1016/j.bbi.2025.01.015
42.
LacagninaMJWillcoxKFBoukelmouneNBavencoffeASankaranarayananIBarrattDTet al. B cells drive neuropathic pain-related behaviors in mice through IgG-fc gamma receptor signaling. Sci Transl Med. (2024) 16(766):eadj1277. 10.1126/scitranslmed.adj1277
43.
SandercockDASmithSHDi GiminianiPEdwardsSA. Histopathological characterization of tail injury and traumatic neuroma development after tail docking in piglets. J Comp Pathol. (2016) 155(1):40–9. 10.1016/j.jcpa.2016.05.003
44.
SandercockDABarnettMWCoeJEDowningACNirmalAJDi GiminianiPet al. Transcriptomics analysis of porcine caudal dorsal root ganglia in tail amputated pigs shows long-term effects on many pain-associated genes. Front Vet Sci. (2019) 6:314. 10.3389/fvets.2019.00314
45.
GiminianiDEdwardsPMalcolmSALeachEMHerskinMCSandercockMSet al. Characterization of short- and long-term mechanical sensitisation following surgical tail amputation in pigs. Sci Rep. (2017) 7(1):4827. 10.1038/s41598-017-05404-y
46.
PabstR. The pig as a model for immunology research. Cell Tissue Res. (2020) 380(2):287–304. 10.1007/s00441-020-03206-9
47.
GerritsMMVan OppenPLeoneSSVan MarwijkHWVan Der HorstHEPenninxBW. Pain, not chronic disease, is associated with the recurrence of depressive and anxiety disorders. BMC Psychiatry. (2014) 14:187. 10.1186/1471-244X-14-187
48.
McWilliamsLACoxBJEnnsMW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Article. Pain. (2003) 106(1-2):127–33. 10.1016/s0304-3959(03)00301-4
49.
BurnsLCRitvoSEFergusonMKClarkeHSeltzerZKatzJ. Pain catastrophizing as a risk factor for chronic pain after total knee arthroplasty: a systematic review. J Pain Res. (2015) 8:21–32. 10.2147/JPR.S64730
50.
PicavetHSVlaeyenJWSchoutenJS. Pain catastrophizing and kinesiophobia: predictors of chronic low back pain. Am J Epidemiol. (2002) 156(11):1028–34. 10.1093/aje/kwf136
51.
DekkerJVan DijkGMVeenhofC. Risk factors for functional decline in osteoarthritis of the hip or knee. Curr Opin Rheumatol. (2009) 21(5):520–4. 10.1097/BOR.0b013e32832e6eaa
52.
RayahinJEChmielJSHayesKWAlmagorOBelisleLChangAHet al. Factors associated with pain experience outcome in knee osteoarthritis. Arthritis Care Res (Hoboken). (2014) 66(12):1828–35. 10.1002/acr.22402
53.
BrownDCBostonRCFarrarJT. Use of an activity monitor to detect response to treatment in dogs with osteoarthritis. J Am Vet Méd Assoc. (2010) 237(1):66–70. 10.2460/javma.237.1.66
54.
KnazovickyDHelgesonESCaseBGruenMEMaixnerWLascellesBD. Widespread somatosensory sensitivity in naturally occurring canine model of osteoarthritis. Pain. (2016) 157(6):1325–32. 10.1097/j.pain.0000000000000521
55.
KnazovickyDTomasAMotsinger-ReifALascellesBDX. Initial evaluation of nighttime restlessness in a naturally occurring canine model of osteoarthritis pain. PeerJ. (2015) 3:e772. 10.7717/peerj.772
56.
Hydbring-SandbergEWalterLWHoglundKSvartbergKSwensonLForkmanB. Physiological reactions to fear provocation in dogs. J Endocrinol. (2004) 180(3):439–48. 10.1677/joe.0.1800439
57.
FeferGPanekWKKhanMZSingerMWestermeyerHDMowatFMet al. Use of cognitive testing, questionnaires, and plasma biomarkers to quantify cognitive impairment in an aging pet dog population. J Alzheimers Dis. (2022) 87(3):1367–78. 10.3233/JAD-215562
58.
HoelJATempletonGBFeferGCaseBCShahAGruenMEet al. Sustained gaze is a reliable in-home test of attention for aging pet dogs. Front Vet Sci. (2021) 8:819135. 10.3389/fvets.2021.819135
59.
GruenMECaseBCFosterMLLazarowskiLFishRELandsbergGet al. The use of an open field model to assess sound-induced fear and anxiety associated behaviors in labrador retrievers. J Vet Behav. (2015) 10(4):338–45. 10.1016/j.jveb.2015.03.007
60.
BrownDCBostonRCCoyneJCFarrarJT. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res. (2007) 68(6):631–7. 10.2460/ajvr.68.6.631
61.
Thonen-FleckCSharonKPEnomotoMLeBouefMRobertsDLGruenMEet al. Physical activity monitors in companion animal chronic pain research-A review focused on osteoarthritis pain. Animals (Basel). (2025) 15(14). 10.3390/ani15142025
Summary
Keywords
measurement, non-rodent models, pain, pain in animals workshop, translational
Citation
Price T, Bachman JL, Nelson AE, Grace PM, Gruen ME, Brown DC, Coetzee JF, Gill M, Johnson C, Oshinsky ML, Robertson SA, Smith ER and Lascelles BDX (2026) Current perspectives: non-rodent models of pain: Pain in Animals Workshop 2025. Front. Pain Res. 7:1999875. doi: 10.3389/fpain.2026.1999875
Received
15 September 2026
Revised
16 October 2026
Accepted
16 October 2026
Published
11 November 2026
Volume
7 - 2026
Edited by
Nick Andrews, Salk Institute for Biological Studies, United States
Reviewed by
Stephan Leisengang, University of Giessen, Germany
Lorena Garcia Menendez, Scripps Research, United States
Updates
Copyright
© 2026 Price, Bachman, Nelson, Grace, Gruen, Brown, Coetzee, Gill, Johnson, Oshinsky, Robertson, Smith and Lascelles.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: B. D. X. Lascelles dxlascel@ncsu.edu
† These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.